FDA Approves BIXLENVO — Gilead Sciences, Inc.

Gilead Sciences has secured FDA approval for Bixlenvo (bictegravir/lenacapavir), a new oral formulation of the long-acting combination therapy, which is expected to solidify the company’s dominance in the highly anticipated long-acting HIV market once it launches in 2026. Market analysts anticipate that the convenience and frequency of treatment administration for this 52-week regimen will significantly disrupt current standard of care protocols, creating a substantial revenue opportunity ahead of the expected release.